Cite
HARVARD Citation
Schetters, S. et al. (2020). Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. Journal for immunotherapy of cancer. 8 (2), p. . [Online].